Recent Publications

Research Papers

(Peer-reviewed)

2021:

46. K.W. Cheng, F. Wang, G.A. Lopez, S. Singamsetty, J. Wood, P.I. Dickson, and T.F. Chou. Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in CHO cells. Biochem. J. 2021. PMID: 34032266. DOI: 10.1042/BCJ20210015.

45. G. Zhang, S. Li, K.W. Cheng, and T.F. Chou. AAA ATPases as Therapeutic Targets: Structure, Function, and Small-Molecule Inhibitors. Eur. J. Med. Chem., 2021, 219, 113446. PMID: 33873056. DOI: 10.1016/j.ejmech.2021.113446.

44. G. Zhang#, S. Li#, F. Wang#, A.C. Jones#, A.F.G. Goldberg, B. Lin, S. Virgil, B.M. Stoltz, R.J. Deshaies#, and T.-F. Chou. A Covalent p97/VCP ATPase Inhibitor can overcome resistance to CB-5083 and NMS-873 in colorectal cancer cells. Eur. J. Med. Chem., 2021, 213, 113148. # These authors contributed equally. PMID: 33476933. DOI: 10.1016/j.ejmech.2020.113148.

43. F. Wang, D.R. Moen, C. Sauni, S. Kan, S. Li, S.Q. Le, B. Lomenick, X. Zhang, S. Ekins, S. Singamsetty, J. Wood, P.I. Dickson, and T.-F. Chou. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice. Mol Pharm. 2021, 18(1): 214-227. PMID: 33320673. DOI: 10.1021/acs.molpharmaceut.0c00831.


2020:

42. F. Wang, S. Li, T. Gan, G.M. Stott, A. Flint, and T.-F. Chou. Allosteric p97 inhibitors can overcome resistance to ATP-competitive p97 inhibitors for potential anti-cancer therapy. ChemMedChem, 2020, 15(8): 685-694. PMID: 32162487. DOI: 10.1002/cmdc.201900722.


2018:

41. M.G. LaPorte, J.C. Burnett, R. Colombo, S.L. Bulfer, C. Alverez, T.-F. Chou, R.J. Neitz, N. Green, W.J. Moore, Z. Yue, S. Li, M.R. Arkin, P. Wipf, D.M. Huryn. Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97. ACS Med. Chem. Lett. 2018, 9(11):1075-1081. PMID: 30429948. DOI: 10.1021/acsmedchemlett.8b00372.

40. J. Li, Y. Zhang, B. Da Silva Sil Dos Santos, F. Wang, Y. Ma, C. Perez, Y. Yang, J. Peng, S.M. Cohen, T.-F. Chou, S.T. Hilton, and R.J. Deshaies. Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11. Cell Chem. Biol. 2018, pii: S2451- 9456(18)30264-2. PMID: 30146242. DOI: 10.1016/j.chembiol.2018.07.012.

39. V. Sanghez, M. Chen, S. Li, T.-F. Chou, M. Iacovino, H.J. Lin, J.L. Lasky, and E.H. Panosyan. Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma. Anticancer Res., 2018, 38, 2627-2634. PMID: 29715082. DOI: 10.21873/anticanres.12504.


2017:

38. M.A. Nakasone, T.A. Lewis, O. Walker, A. Thakur, W. Mansour, C.A. Castañeda, J.L. Goeckeler-Fried, F. Parlati, T.-F. Chou, O. Hayat, D. Zhang, C.M. Camara, S.M. Bonn, U.K. Nowicka, S. Krueger, M.H. Glickman, J.L. Brodsky, R.J. Deshaies, and D. Fushman. Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway. Structure. 2017, 25,1839-1855. PMID: 29153505. DOI: 10.1016/j.str.2017.10.007.

37. V. Sanghez, A. Luzzi, D. Clarke, D. Kee, S. Buder, D. Rux, M. Osawa, J. Madrenas, T.-F. Chou, M. Kyba, M. Iacovino. Notch activation is required for downregulation of HoxA3-dependent endothelial cell phenotype during blood formation. PLoS One, 2017, 12, e0186818. PMID: 29073173. DOI: 10.1371/journal.pone.0186818.

36. C. Perez, J. Li, F. Parlati, M. Rouffet, Y. Ma, H.J. Zhou, A.L. Mackinnon, T.-F. Chou, R.J. Deshaies, and S.M. Cohen. Correction to Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J. Med. Chem., 2017; 60(7):3217. PMID: 28328205. DOI: 10.1021/acs.jmedchem.7b00390.

35. P. Bastola, F. Wang, M.A. Schaich, T. Gan, B.E. Freudenthal, T.-F. Chou, and J. Chien. Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Cell Death Discov., 2017, 60(7):3217. PMID: 29367883. DOI: 10.1038/cddiscovery.2017.65.

34. R. Shah #, T.-F. Chou #, K.M. Maize, A. Strom, B.C. Finzel, and C.R. Wanger. Inhibition by Divalent Metal Ions of Human Histidine Triad Nucleotide Binding Protein1 (hHint1), a Regulator of Opioid Analgesia and Neuropathic Pain. Biochem. Biophys. Res. Commun., 2017, 491,760-766. # These authors contributed equally. PMID: 28739258. DOI: 10.1016/j.bbrc.2017.07.111.

33. Y.J. Lee, T.-F. Chou, S.K. Pittman, and C.C. Weihl. Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA domain Ubiquitination. Cell Rep., 2017, 19,188-202. PMID: 28380357. DOI: 10.1016/j.celrep.2017.03.030.

32. A. Segura-Cabrera, R. Tripathi, X. Zhang, L. Gui, T.-F. Chou, and K. Komurov. A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase. Sci. Rep. 2017, 7,44912. PMID: 28322292. DOI: 10.1038/srep44912.

31. C. Perez, J. Li, F. Parlati, M. Rouffet, Y. Ma, A.L. Mackinnon, T.-F. Chou, R.J. Deshaies, and S.M. Cohen. Discovery of an Inhibitor of the Proteasome Subunit Rpn11. J. Med. Chem. 2017, 60, 1343-1361. PMID: 28191850. DOI: 10.1021/acs.jmedchem.6b01379.


2016:

30. S.L. Bulfer, T.-F. Chou, M.R. Arkin. p97 disease mutations modulate nucleotide-induced conformation to alter protein-protein interactions. ACS Chem Biol. 2016, 11, 2112-2116. PMID: 27267671. DOI: 10.1021/acschembio.6b00350.

29. L. Gui, X. Zhang, K. Li, K. Frankowski, S. Li, D. Wong, D.R. Moen, P.R. Porubsky, H.J. Lin, F.J. Schoene, T.-F. Chou. Evaluating p97 Inhibitor Analogues for Potency against p97-p37 and p97-Npl4-Ufd1 Complexes. ChemMedChem, 2016, 11, 953-957. PMID: 27043824. DOI: 10.1002/cmdc.201600036.


2015:

28. M. Liu, L. Lin, T. Gebremariam, G. Luo, C. D. Skory, S. W. French, T.-F, Chou, J.E. Jr. Edwards, and A.S. Ibrahim. Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine. PLoS Pathog. 2015, 11, e1004842. PMID: 25974051. DOI: 10.1371/journal.ppat.1004842.

27. N.U. Jerath, C.D. Crockett, S.A. Moore, M.E. Shy, C.C. Weihl, T.-F. Chou, M.A. Gonzalez, S. Zuckner, and A. Swenson. Rare Manifestation of a c.290 C>T, p.Gly97Glu VCP Mutation. Case Rep Genet. 2015; 2015:239167. PMID: 25878907. DOI: 10.1155/2015/239167.

26. X. Zhang, L. Gui, X. Zhang, S. L. Bulfer, V. Sanghez, D. Wong, Y.J. Lee, L. Lehmann, J.S. Lee, P.-Y. Shih, H.J. Lin, M. Iacovino, C.C. Weihl, M.R. Arkin, T. Wang, T.-F. Chou. Altered cofactor regulation with disease associated p97/VCP mutations. Proc. Natl. Acad. Sci. USA, 2015, 112, E1705-1714. PMID: 25775548. DOI: 10.1073/pnas.1418820112.

25. C.C. Weihl, R.H. Baloh, Y. Lee, T.-F. Chou, S.K. Pittman, G. Lopate, P. Allred, J. Jockel-Balsarotti, A. Pestronk, and M.B. Harms. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord., 2015 Apr;25(4):289-296. PMID: 25617006. DOI: 10.1016/j.nmd.2014.12.009.

24. C. Fang, L. Gui, X. Zhang, D.R. Moen, K. Li, K.J. Frankowski, H.J. Lin, F.J. Schoene, and T.-F. Chou. Evaluating p97 inhibitor analogues for their domain-selectivity and potency against the p97-p47 complex. ChemMedChem, 2015, 10, 52-56. PMID: 25377500. DOI: 10.1002/cmdc.201402420.


2014:

23. M. Kato, T.-F. Chou, C.Z. Yu, J. Demodena, and P.W. Sternberg. LINKIN, a new transmembrane protein necessary for cell adhesion. eLife. 2014, 3, e04449. PMID: 25437307. DOI: 10.7554/eLife.04449.

22. A. Sapir, A. Tsur, T. Koorman, K. Ching, A. Bardenheier, L. Podolsky, U. Bening-Abu-Shach, M. Boxem, T.-F. Chou, L. Broday, and P.W. Sternberg. Controlled sumoylation of the mevalonate pathway enzyme HMGS-1 regulates metabolism during aging. Proc. Natl. Acad. Sci. USA. 2014, 111, E3880-3889. PMID: 25187565. DOI: 10.1073/pnas.1414748111.

21. M.A. Gonzalez, S. Feely, F. Speziani, A. Strickland, M. Danzi, C. Bacon, Y. Lee, T.-F. Chou, S.H. Blanton, C.C. Weihl, S. Zuchner, and M. Shy. A Novel Mutation in VCP Causes Charcot-Marie-Tooth Type 2 Disease. Brain, 2014, 137(11), 2897-2902. PMID: 25125609. DOI: 10.1093/brain/awu224.

20. T.-F. Chou*, S. L. Bulfer, C.C. Weihl, K. Li, L.G. Lis, M.A. Walters, F.J. Schoenen, H.J. Lin, R.J. Deshaies, and M.R. Arkin. Specific Inhibition of p97/VCP ATPase and Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase domains. J. Mol. Biol. 2014, 426, 2886-2899. PMID: 24878061. DOI: 10.1016/j.jmb.2014.05.022.


2013:

19. X. Zhou, T.-F. Chou, B.E. Aubol, C.J. Park, R. Wolfenden, J. Adams, and C.R. Wagner. Kinetic Mechanism of Human Histidine Triad Nucleotide Binding Protein 1 (Hint1). Biochemistry, 2013, 52, 3588-3600. PMID: 23614568. DOI: 10.1021/bi301616c.

18. T.-F. Chou*, K. Li, K. Frankowski, F.J. Schoenen, and R.J. Deshaies*. Structure- Activity Relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. ChemMedChem. 2013, 8,297-312. PMID: 23316025. DOI: 10.1002/cmdc.201200520.


2011:

17. S. Bardaweel, B. Ghosh, T.-F. Chou, M.J. Sadowsky, and C.R. Wagner. E. coli histidine triad nucleotide binding protein 1 (ecHinT) is a catalytic regulator of D-alanine dehydrogenase (DadA) activity in vivo. PLoS One. 2011, 6, e20897. PMID: 21754980. DOI: 10.1371/journal.pone.0020897.

16. T.-F. Chou*, and R. J. Deshaies*. Development of p97 AAA ATPase inhibitors. Autophagy. 2011, 7, 1091-1092. PMID: 21606684. DOI: 10.4161/auto.7.9.16489.

15. G. Birkus, N. Kutty, C.R. Frey, R. Shribata, T.-F. Chou, C.R. Wagner, M. McDermott, and T. Cihlar. Role of cathepsin A and lysosomes in the intracellular activation of novel anti-papillomavirus agent GS-9191. Antimicrob. Agents Chemother. 2011, 55, 2166 - 2173. PMID: 21383096. DOI: 10.1128/AAC.01603-10.

14. T.-F. Chou*, S. J. Brown, D. Minond, B.E. Nordin, K. Li, A.C. Jones, P. Chase, P. R. Porubsky, B.M. Stoltz, F.J. Schoenen, M.P. Patricelli, P. Hodder, H. Rosen, and R. J Deshaies*. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc. Natl. Acad. Sci. USA. 2011, 108, 4834 - 4839. PMID: 21383145. DOI: 10.1073/pnas.1015312108.

13. T.-F. Chou*, and R.J. Deshaies*. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J. Biol. Chem. 2011, 286, 16546 - 16554. PMID: 21343295. DOI: 10.1074/jbc.M110.215319.


2010:

12. S. Bardaweel, J. Pace, T.-F. Chou, V. Cody, and C.R. Wagner. Probing the impact of the echinT c-terminal domain on structure and catalysis. J. Mol. Biol. 2010, 404, 627 - 638. PMID: 20934431. DOI: 10.1016/j.jmb.2010.09.066.


2009:

11. J. Cheng, X. Zhou, T.-F. Chou, B. Ghosh, B. Liu, and C.R. Wagner. Identification of the amino acid-AZT-phosphoramidase by affinity T7 phage display selection. Bioorg. Med. Chem. Lett. 2009, 19, 6379 - 6381. PMID: 19825512. DOI: 10.1016/j.bmcl.2009.09.067.


2008:

10. T.-F. Chou, C. So, B.R. White, J.C.T. Carlson, M. Sarikaya, and C.R. Wagner. Enzyme nanorings. ACS Nano 2008, 2, 2519 - 2525. PMID: 19206287. DOI: 10.1021/nn800577h.

9. P. Ghosh, J. Chen, T.-F. Chou, Y. Jia, S. Avdulov, P. B. Bitterman, V. A. Polunovsky, and C.R. Wagner. Expression, purification and characterization of recombinant mouse initiation factor eIF-4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr. Purif., 2008, 60, 132 - 139. PMID:18479935. DOI: 10.1016/j.pep.2008.03.024.


2007:

8. T.-F. Chou, Y. Y. Sham, and C. R. Wagner. The Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate specificity. Biochemistry, 2007, 46, 13074 - 13079. PMID:17939685. DOI:10.1021/bi701244h.

7. T.-F. Chou, J. Cheng, I. B. Tikh, and C. R. Wagner. Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily. J. Mol. Biol.2007, 373, 978 - 989. PMID: 17870088. DOI: 10.1016/j.jmb.2007.08.023.

6. T.-F. Chou, I. B. Tikh, B.A.C. Horta, B. Ghosh, R.B. de Alencastro, and C. R. Wagner. Engineered monomeric human histidine triad nucleotide binding protein 1 hydrolyzes fluorogenic acyl -adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate. J. Biol. Chem. 2007, 282, 15137 - 15147. PMID:17337452. DOI:10.1074/jbc.M606972200.

5. T.-F. Chou, J. Baraniak, R. Kaczmarek, X. Zhou, J. Cheng, B. Ghosh, and C. R. Wagner. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and E. coli histidine triad nucleotide binding proteins (Hint1). Mol. Pharma. 2007, 4, 208 - 217. PMID:17217311. DOI:10.1021/mp060070y.

4. T.-F. Chou and C. R. Wagner. Lysyl-tRNA synthetase generated lysyl-adenylate is a substrate for histidine triad nucleotide binding proteins (Hints). J. Biol. Chem. 2007, 282, 4719 - 4727. PMID:17158446. DOI:10.1074/jbc.M610530200.


2006:

3. J. C. T. Carlson, S. S. Jena, F. Flenniken, T.-F. Chou, R. A. Siegel, and C. R. Wagner. Chemically controlled self-assembly of protein nanorings. J. Am. Chem. Soc. 2006, 128, 7630 - 7638.1. PMID:16756320. DOI:10.1021/ja060631e.


2005:

2. T.-F. Chou, Bieganowski, P., Shilinski, K., Cheng, J., Brenner, C., and Wagner, C. R. 31P-NMR and genetic analysis establish hinT as the only Escherichia coli purine nucleoside phosphoramidase and as essential for growth under high salt conditions. J. Biol. Chem. 2005, 280, 15356 - 15361. 1. PMID: 15703176 . DOI: 10.1074/jbc.M500434200.


2004:

1. J. Kim, T.-F. Chou, Griesgraber, G. W., and Wagner, C. R. Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LCESI- MS/MS. Mol. Pharm. 2004, 1, 102 - 111. PMID: 15832506. DOI: 10.1021/mp0340338.